Veracyte Stock Performance
| VCYT Stock | USD 27.51 0.07 0.25% |
The entity has a beta of 1.18, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Veracyte will likely underperform. At this point, Veracyte has a negative expected return of -0.0757%. Please make sure to validate Veracyte's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Veracyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Veracyte is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
1 | Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 VCYT Stock News | 04/16/2025 |
2 | Disposition of 15672 shares by Febbo Phillip G. of Veracyte at 33.84 subject to Rule 16b-3 | 04/25/2025 |
3 | Disposition of 5748 shares by Marc Stapley of Veracyte at 31.55 subject to Rule 16b-3 | 05/01/2025 |
4 | Veracyte, Inc. Shares Acquired by AQR Capital Management LLC | 05/07/2025 |
5 | Veracyte Inc Unveils Promising Cancer Diagnostic Findings at ASCO 2025 VCYT stock news | 05/28/2025 |
6 | Disposition of 9399 shares by Marc Stapley of Veracyte at 26.74 subject to Rule 16b-3 | 06/02/2025 |
7 | Disposition of 2809 shares by John Leite of Veracyte at 27.2018 subject to Rule 16b-3 | 06/04/2025 |
8 | Veracyte Down 13.6 percent Since Last Earnings Report Can It Rebound | 06/06/2025 |
9 | Veracyte Fell Despite Reporting Revenue Growth and Improved Profitability | 06/09/2025 |
10 | Disposition of 4589 shares by Bhanji Muna of Veracyte at 26.6652 subject to Rule 16b-3 | 06/13/2025 |
11 | Insider Sell Karin Eastham Sells Shares of Veracyte Inc | 06/17/2025 |
12 | Disposition of 6754 shares by Febbo Phillip G. of Veracyte at 34.76 subject to Rule 16b-3 | 06/24/2025 |
13 | Option Care Health Shows Improved Relative Strength Still Shy Of Benchmark - Investors Business Daily | 06/30/2025 |
| Begin Period Cash Flow | 217.3 M |
Veracyte Relative Risk vs. Return Landscape
If you would invest 2,953 in Veracyte on April 6, 2025 and sell it today you would lose (202.00) from holding Veracyte or give up 6.84% of portfolio value over 90 days. Veracyte is currently does not generate positive expected returns and assumes 2.8252% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Veracyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Veracyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Veracyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Veracyte, and traders can use it to determine the average amount a Veracyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0268
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VCYT |
Estimated Market Risk
| 2.83 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Veracyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Veracyte by adding Veracyte to a well-diversified portfolio.
Veracyte Fundamentals Growth
Veracyte Stock prices reflect investors' perceptions of the future prospects and financial health of Veracyte, and Veracyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Veracyte Stock performance.
| Return On Equity | 0.0286 | ||||
| Return On Asset | 0.0194 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.92 B | ||||
| Shares Outstanding | 78.31 M | ||||
| Price To Earning | (10.61) X | ||||
| Price To Book | 1.80 X | ||||
| Price To Sales | 4.65 X | ||||
| Revenue | 445.76 M | ||||
| Gross Profit | 326.41 M | ||||
| EBITDA | 49.2 M | ||||
| Net Income | 24.14 M | ||||
| Cash And Equivalents | 170.11 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 50.74 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 15.26 X | ||||
| Cash Flow From Operations | 75.1 M | ||||
| Earnings Per Share | 0.42 X | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (443.98 M) | ||||
| Current Asset | 47.91 M | ||||
| Current Liabilities | 14.72 M | ||||
About Veracyte Performance
Assessing Veracyte's fundamental ratios provides investors with valuable insights into Veracyte's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Veracyte is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people.Things to note about Veracyte performance evaluation
Checking the ongoing alerts about Veracyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Veracyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Veracyte generated a negative expected return over the last 90 days | |
| Veracyte is unlikely to experience financial distress in the next 2 years | |
| Veracyte has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Option Care Health Shows Improved Relative Strength Still Shy Of Benchmark - Investors Business Daily |
- Analyzing Veracyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Veracyte's stock is overvalued or undervalued compared to its peers.
- Examining Veracyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Veracyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Veracyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Veracyte's stock. These opinions can provide insight into Veracyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.